6
S. K. PANDEY ET AL.
(–COOCH3). Anal. Calcd for C9H8 N2O2SCl2 (279.14): C, (500 MHz, CDCl3, 25 ꢄC): dH; 11.46 (s, 1H, –CS–NH–), 8.34
38.73; H, 2.89; N, 10.04. Found: C, 38.68; H, 2.86; N, 9.98%.
(s, 1H,–CO–NH–), 7.58 (d, 1H, J ¼ 6.1 Hz, –C6H4), 7.54 (dd,
1H, J ¼ 6.1, 2.5 Hz, –C6H4), 7.51 (dt,1H, J ¼ 6.1, 2.5, 2.0 Hz,
–C6H4), 6.97 (d, 1H, J ¼ 2.5 Hz, –C6H4), 4.23 (t, 2H,
N-(2, 4-dichlorophenyl)-N’-(ethoxycarbonyl)
thiocarbamide (2)
J ¼ 7.0 Hz, –OCH2), 2.57 (m, 2H, –(CH2)–), 1.69 (m, 2H,
2x(–CH2), 0.92 (t, 3H, J ¼ 5.0 Hz, –CH3). 13C NMR
(125 MHz, CDCl3, 25ꢄ): 181.7 (C@S), 156.9(C@O), 149.3,
147.4, 142.8, 136.4, 129.9, 120.6 (Ar–C), 67.2 (–OCH2),
28.6–22.2 –(CH2)3–, 13.9 (–CH3). Anal. Calcd for
C13H17N3O4S (311.35): C, 50.15; H, 5.50; N, 13.50. Found:
C, 50.11; H, 5.47; N, 13.47%.
Yield: 90%; dark yellow; m.p.; 165–166 ꢄC; FT–IR (KBr,
cmꢆ1): 3407, 3155, ꢀ(N–H); 3091, ꢀ(Ar, C–H); 2940,
ꢀ(Aliphatic, C–H); 1680, ꢀ(–C ¼ O); 1196, ꢀ(NCN); 741,
1
ꢀ(C ¼ S); 650, ꢀas(C–Cl); 452, ꢀs(C–Cl). H NMR (500 MHz,
DMSO-d6, 25 ꢄC): dH; 11.51 (s, 1H, –CS–NH–), 11.50 (s, 1H,
–CO–NH–); 7.89 (s, 1H, Ar–H); 7.68 (d, 1H, J ¼ 9.0 Hz,
Ar–H); 7.43 (d, 1H, J ¼ 6.5 Hz, Ar–H); 4.20 (q, 2H, J ¼ 7.5 Hz,
–OCH2–); 1.23 (t, 3H, J ¼ 6.5 Hz, –CH3).13C NMR (125, MHz,
DMSO-d6, 25 ꢄC): 180.2 (C@S), 154.1 (C@O), 135.3, 131.9,
130.4, 130.1,129.4, 128.1(Ar–C), 62.7 (–OCH2–), 14.9, (–CH3).
Anal. Calcd for C10H10 N2O2SCl2 (293.17): C, 40.97; H, 3.44;
N, 9.56. Found: C, 40.75; H, 3.30; N, 9.41%.
Biological evaluations
Cell lines
Seven human cancer cell lines, namely cervical (2008 and
*
C13 ), colorectal (HT29 and HCT116) and ovarian carcin-
oma (IGROV-1, A2780 and A2780/CP), were used. Among
*
these, C13 and A2780/CP are cisplatin (ccDDP)-resistant
cells.[52,53] Cells were grown as monolayers in RPMI 1640
medium containing 10% heat-inactivated fetal bovine serum
and 50 mg/mL gentamycin sulfate. All cell media and serum
were purchased from Lonza (Verviers, Belgium). Cultures
were equilibrated with humidified 5% CO2 in air at 38 ꢄC.
All studies were performed in mycoplasma negative cells, as
routinely determined with the MycoAlert Mycoplasma
detection kit (Lonza, Walkersville, MD, USA).
N-(2, 4-dichlorophenyl)-N’-(2, 2, 2-
trichloroethoxycarbonyl) thiocarbamide (3)
Yield: 80%; yellow; m.p.; 130–131 ꢄC; FT–IR (KBr, cmꢆ1):
3450, 3165, ꢀ(N–H); 3047, ꢀ(Ar, C–H); 2935, ꢀ(Aliphatic,
C–H); 1685, ꢀ(–C ¼ O); 1148, ꢀ(NCN); 743, ꢀ(C ¼ S); 641,
ꢀas(C–Cl); 457, ꢀs(C–Cl). 1H NMR (500 MHz, DMSO-d6,
25 ꢄC): dH; 12.00 (s, 1H, –CS–NH–), 11.23 (s, 1H, –CO–NH–);
7.79 (s, 1H, Ar-H); 7.70 (d, 1H, J ¼ 8.0 Hz, Ar–H); 7.46 (d, 1H,
J ¼ 6.5 Hz, Ar–H); 4.98 (s, 2H, –OCH2). 13C NMR (125, MHz,
DMSO-d6, 25 ꢄC): 180.0 (C@S), 152.4 (C@O), 135.4, 132.2,
130.9, 130.5, 129.5, 128.0 (Ar–C), 95.4(–OCH2), 74.6 (–CCl3).
Anal. Calcd for C10H7N2O2SCl5 (396.50): C, 30.29; H, 1.78; N,
7.07. Found: C, 30.20; H, 1.76; N, 7.02%.
In vitro cytotoxicity screening
In vitro cytotoxicity of compounds in this study was deter-
mined by MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide) assay method.[54,55] The cells were
seeded into 96-well plates and cultured overnight. Various
concentrations of the test compounds dissolved in DMSO
were then added and incubated for 72 h. After incubation,
the medium was removed and fresh culture medium 100 mL
containing 0.5 mg mLꢆ1MTT (3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenytetrazolium bromide, Sigma Aldrich, Bengaluru,
India) was added and then, the plates were incubated at
38 ꢄC for 4 h. The medium was removed and 100 mL DMSO
was added to dissolve the dark blue crystals. After incuba-
tion for 30 min at room temperature to ensure that all crys-
tals were dissolved, absorbance at 500 nm was measured
using an ELISA plate reader at 570 nm with a reference
wavelength of 650 nm.
N-(2, 4-dichlrophenyl)-N’-(pentoxycarbonyl)
thiocarbamide (4)
Yield: 80%; light yellow; m.p.; 90–91 ꢄC; FT–IR (KBr, cmꢆ1):
3467, 3156, ꢀ(N–H); 3117, ꢀ(Ar, C–H); 2950, ꢀ(Aliphatic
C–H); 1690, ꢀ(–C ¼ O); 1167, ꢀ(NCN); 743, ꢀ(C ¼ S); 657,
1
ꢀas(C–Cl); 455, ꢀs(C–Cl). H NMR (500 MHz, CDCl3, 25 ꢄC):
dH; 11.66 (s, 1H, –CS–NH–), 8.33 (s, 1H,–CO–NH–), 8.32 (d,
1H, J ¼ 3.0 Hz, –C6H3), 7,46 (dd, 1H, J ¼ 8.5, 3.1 Hz, –C6H3),
6.45(d, 1H, J ¼ 8.5 Hz, –C6H3), 4.25 (t, 2H, J ¼ 7.0 Hz,
–OCH2), 2.43 (m, 2H, –(CH2)–), 1.71 (m, 4H, 2x(–CH2), 0.93
(t, 3H, J ¼ 4.0 Hz, –CH3). 13C NMR (125 MHz, CDCl3, 25 ꢄC):
178.1 (C@S), 152.7 (C@O), 133.6, 132.2, 129.3, 128.5, 127.1,
126.9 (Ar–C), 67.3 (–OCH2), 27.7 ꢆ 21.2 –(CH2)3–, 13.2
(–CH3). Anal. Calcd for C13H16N2O2SCl2 (335.25): C, 46.58;
H, 4.81; N, 8.36. Found: C, 46.45; H, 4.77; N, 8.30%.
Conclusions
We have synthesized five new N-Aryl-N’-alkoxycarbonyl thi-
ocarbamide derivatives. The structure of these compounds
was confirmed by FT-IR, 1H and 13C NMR spectroscopic
and single-crystal X-ray analysis of compounds 2 and 5. The
intermolecular contacts of compounds 2 and 5 were exam-
ined by Hirshfeld surfaces and fingerprint plots. The
molecular structure of the compounds is virtually planar
N-(4-nitrophenyl)-N’-(pentoxycarbonyl)
thiocarbamide (5)
Yield: 78%; dark yellow; m.p.; 140–141 ꢄC; FT–IR (KBr,
cmꢆ1): 3430, 3126, ꢀ(N–H); 3098, ꢀ(Ar, C–H); 2923,
ꢀ(Aliphatic, C–H); 1703, ꢀ(–C ¼ O); 1547, ꢀas(–NO2); 1345,
ꢀs(–NO2); 1169, ꢀ(NCN); 735, ꢀ(C ¼ S). 1H NMR favoring the existence of N–HꢀꢀꢀO and C–HꢀꢀꢀO